Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mallinckrodt (MNK) delivered earnings and revenue surprises of 16.31% and -2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Mallinckrodt (MNK) Q1 Earnings Surpass Estimates

Shares of Mallinckrodt (NYSE:MNK) were unchanged in pre-market trading after the company reported Q1 results.

Recap: Mallinckrodt Q1 Earnings

Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for

New York state brought civil charges on Tuesday accusing Mallinckrodt Plc  of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.

New York charges Mallinckrodt with insurance fraud over opioid claims

New York has charged Mallinckrodt Plc  with insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, leading to medically unnecessary prescriptions.

New York charges Mallinckrodt with insurance fraud related to opioids

Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates Again

Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.

Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?

Mallinckrodt: Back To The Negotiating Table

Mallinckrodt (NYSE: MNK) shares are trading higher on Wednesday. The company announced it received clearance from Health Canada to start on a pilot trial of high dose inhaled nitric oxide therapy for coronavirus infection and associated lung complications.

Why Mallinckrodt's Stock Is Trading Higher Today

Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.

Mallinckrodt Completes NDA Submission for Kidney Failure Drug

Shares of Mallinckrodt PLC MNK, -12.64% tumbled 21% in premarket trading Monday, after the drug maker said it would pay about $650 million for the period from Jan.

Mallinckrodt's stock plunges on court decision regarding Acthar Gel rebates

Biogen

Gilead Sciences

Inovio Pharmaceuticals

Eli Lilly

Roche Holding AG

Vir Biotechnology

Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off

Mallinckrodt's (MNK) proposed global opioid settlement receives support from New York State Attorney General, taking the total support count to 48 states and territories.

Mallinckrodt Up on New York's Support for Opioid Settlement

Mallinckrodt: Last Ditch Attempt By CMS

Shares of Mallinckrodt PLC MNK, -26.77% plummeted 26% in afternoon trading Tuesday, to pace all NYSE decliners, after Dow Jones Newswire reported that U.S.

Mallinckrodt's stock plunges after report of DOJ suit for alleged underpayment of Medicaid rebates

The United States sued a unit of the drugmaker Mallinckrodt Plc on Tuesday, accusing it of defrauding Medicaid out of hundreds of millions of dollars as a result of "extraordinary" price increases for its drug Acthar Gel.

U.S. sues Mallinckrodt, accuses drugmaker of defrauding Medicaid

The U.S. government said on Tuesday it filed a lawsuit accusing a unit of the drugmaker Mallinckrodt Plc  of improperly avoiding the payment of hundreds of millions of dollars in Medicaid rebates as a result of large drug price increases.

U.S. joins False Claims Act lawsuit against Mallinckrodt

Mallinckrodt: A Complex Transaction Signaling A New Beginning

Mallinckrodt (MNK) signs a $1.6-billion agreement for its ongoing opioid litigation and reports better-than-expected Q4 results.

Mallinckrodt Gains on Opioid Settlement, Beats on Q4 Earnings

Mallinckrodt: A Huge Gamble, But It May Survive

Mallinckrodt Plc on Tuesday said it had agreed to a $1.6 billion settlement proposal in which its generic drug business would file for bankruptcy in order to resolve thousands of lawsuits alleging it helped fuel the U.S. opioid epidemic.

Mallinckrodt agrees to $1.6 billion opioid settlement, unit to seek bankruptcy

The $1.6 billion deal would release the pharmaceutical company from all opioid-related claims.

Mallinckrodt Reaches Tentative Settlement Deal on Opioid Lawsuits

Mallinckrodt plc (MNK) CEO Mark Trudeau on Q4 2019 Results - Earnings Call Transcript

The drugmaker topped Wall Street's estimates for both the top and bottom lines. And it had some other big news that overshadowed its Q4 performance.

News for Mallinckrodt PLC Stock (MNK)